Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Nov 4;11:21645. doi: 10.1038/s41598-021-00976-2

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Cortical α2-AR antagonism blocks VNS-driven map reorganization without altering α2-AR protein expression. (A) Unlike yohimbine, the selective α2-AR antagonist RS79948 did not increase total motor map area in VNS-treated subjects (n = 4). (B) RS79948 infusion blocked VNS-induced expansion of the PFL representation. In (A), (B), *p < 0.05, **p < 0.01, Tukey post hoc comparison. (C–E) Intracortical infusion of yohimbine did not significantly alter the protein expression of α2A adrenoreceptor (α2A-AR, D) or α2C adrenoreceptor (α2C-AR, E) subtypes in M1. In (C), protein samples used to quantify expression of α2A-AR (top) and α2C-AR (bottom) were processed in parallel on separate gels. Control signals (GAPDH) were then detected from both membranes in parallel after stripping the primary antibodies of each α2-AR subtype. Images in (C) have been cropped to improve the clarity and conciseness of the presentation; full-length blots are presented in Supplementary Fig. 4. In D-E, α2A-AR (D) and α2C-AR (E) signal intensity is presented relative to same-column GAPDH intensity. Filled circles denote data for individual subjects; error bars denote SEM.